Following a strategic review by executive management, the Company sharpened its focused investment on its most important assets. These include its three clinical-stage active immunotherapy programs, two of which are in ongoing pharma collaborations, and its most promising small molecule programs targeting NLRP3, Tau and a-synuclein. As a result, the Company has reduced its workforce by around 30% and extended its cash for operations to the end of Q3 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACIU:
- AC Immune appoints Mummery as Chair of Clinical Advisory Board
- AC Immune’s ACI-24.060 Study: A Potential Game-Changer in Alzheimer’s Treatment
- AC Immune’s Innovative PET Tracer Study: A Potential Game-Changer for Neurodegenerative Diagnostics
- AC Immune’s Innovative PET Radioligand Study: A Potential Game-Changer in Neurodegenerative Diagnostics
- AC Immune SA: Pioneering Innovations in Neurodegenerative Disease Treatment and Diagnostics